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Background
Multiparameter flow cytometric analysis of bone marrow and peripheral blood cells has proven
to be of help in the diagnostic workup of myelodysplastic syndromes. However, the usefulness
of flow cytometry for the detection of megakaryocytic and platelet dysplasia has not yet been
investigated. The aim of this pilot study was to evaluate by flow cytometry the diagnostic and
prognostic value of platelet dysplasia in myelodysplastic syndromes.
Design and Methods
We investigated the pattern of expression of distinct surface glycoproteins on peripheral blood
platelets from a series of 44 myelodysplastic syndrome patients, 20 healthy subjects and 19
patients with platelet alterations associated to disease conditions other than myelodysplastic
syndromes. Quantitative expression of CD31, CD34, CD36, CD41a, CD41b, CD42a, CD42b
and CD61 glycoproteins together with the PAC-1, CD62-P, fibrinogen and CD63 platelet acti-
vation-associated markers and platelet light scatter properties were systematically evaluated.   
Results
Overall, flow cytometry identified multiple immunophenotypic abnormalities on platelets of
myelodysplastic syndrome patients, including altered light scatter characteristics, over- and
under expression of specific platelet glycoproteins and asynchronous expression of CD34;
decreased expression of CD36 (n=5), CD42a (n=1) and CD61 (n=2), together with reactivity for
CD34 (n=1) were only observed among myelodysplastic syndrome cases, while other alter-
ations were also found in other platelet disorders. Based on the overall platelet alterations
detected for each patient, an immunophenotypic score was built which identified a subgroup
of myelodysplastic syndrome patients with a high rate of moderate to severe alterations
(score>1.5; n=16) who more frequently showed thrombocytopenia, megakaryocytic dysplasia
and high-risk disease, together with a shorter overall survival.
Conclusions
Our results show the presence of altered phenotypes by flow cytometry on platelets from
around half of the myelodysplastic syndrome patients studied. If confirmed in larger series of
patients, these findings may help refine the diagnostic and prognostic assessment of this group
of disorders. 
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immunophenotyping.
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ABSTRACT
Introduction
Myelodysplastic syndromes (MDS) are a heteroge-
neous group of clonal hematopoietic stem cell disorders
characterized by bone marrow (BM) failure and increased
risk of transformation to acute myeloid leukemia (AML).1
Usually, MDS patients are elderly and they already show
anemia, leukopenia and/or thrombocytopenia at presen-
tation.2 Conventional diagnosis of MDS is based on a
combination of morphology and cytogenetics, besides
exclusion of other disorders as primary cause for cytope-
nia/dysplasia.3 However, in some cytopenic patients,
diagnosis of MDS remains a challenge. Because of this,
more refined definitions and criteria for the diagnosis of
MDS have been recently proposed;4 among other tests
(diagnostic co-criteria), multiparameter flow cytometry
immunophenotyping has been reported to be a useful
additional diagnostic tool.
Over the past two decades, a great number of
immunophenotypic alterations have been described in
both BM and peripheral blood (PB) cells from MDS
patients through the use of multiparameter flow cytome-
try (MFC) immunophenotyping.4,5 Immunophenotypic
alterations most frequently involve myeloblasts, CD34+ B-
cell precursors as well as the CD34- precursors,6-9 e.g.
maturing neutrophil, monocytic and erythroid cells.10-16 On
the other hand, few studies have been reported in which
the BM megakaryocytic compartment is evaluated and, to
the best of our knowledge, no attempts have been made
to investigate the potential presence of phenotypic alter-
ations in PB platelets by MFC. For this reason, an analysis
of megakaryocytic lineage by MFC is usually excluded
from consensus recommendations on MFC immunophe-
notyping of MDS due to the limited data available.17
Both the immunophenotype and DNA ploidy status of
BM megakaryocytic precursors from healthy subjects and
MDS patients have been previously investigated by
MFC.18 However, due to their large size, low frequency
(<0.05%) in BM, increased fragility and adhesion proper-
ties with a tendency to aggregate,19,20 analysis of BM
megakaryocytes typically requires screening of large vol-
umes of sample, and complex sample preparation proce-
dures have been used.18,21,22 Consequently, immunopheno-
typing of megakaryocytic BM cells by MFC has never
become routine in MDS.
Despite all of this, it could be hypothesized that a
potentially useful alternative cellular target to evaluate
the presence of megakaryocytic dysplasia in MDS
patients by MFC, could be PB platelets through the
assessment of the immunophenotypic pattern of expres-
sion of multiple surface glycoproteins (GP) in combina-
tion or not with other functional properties of platelets.
In this pilot study, we evaluated the pattern of expres-
sion of multiple surface GP on PB platelets from a series
of 44 MDS patients versus normal PB platelets, in order to
identify potential alterations that could contribute to the
diagnosis of megakaryocytic dysplasia in MDS and eval-
uation of its prognostic impact on overall patient survival.
Design and Methods
Patients, controls and samples
PB samples from 44 MDS patients were collected into
VacutainerTM tubes containing sodium citrate (Becton-Dickinson,
New Jersey, USA). The study was approved by the local institu-
tional review boards. All patients and control subjects gave their
informed consent prior to entering the study, in line with the
guidelines of the local ethics committees and the Declaration of
Helsinki. During PB collection, the first 2 mL were systematical-
ly discharged. None of the subjects was taking aspirin or other
platelet-activating medication, had received blood transfusions
during the preceding two weeks, or had been treated with
hematopoietic growth factors or chemotherapy for the previous
six months. 
Diagnosis of MDS was established according to the World
Health Organization (WHO) criteria based on clinical data, mor-
phological analysis of PB and BM smears, and cytogenetic stud-
ies, after excluding other diseases which could potentially con-
tribute to BM dysplasia and/or cytopenias.3 The distribution of
the MDS patients according to the WHO classification was:
refractory cytopenia with unilineage dysplasia (n=12), refractory
anemia (RA) (n=9), and refractory thrombocytopenia (RT) (n=3);
RA with ringed sideroblasts (RARS) (n=9); refractory cytopenia
with multilineage dysplasia (RCMD) (n=14); RA with excess of
blasts type 1 (RAEB-1) (n=2); RAEB-2 (n=5), and 5q- syndrome
(n=2). Mean age was 74±11 years (median 76 years, range 45-90
years). There were 14 males and 30 females.
According to the International Prognostic Scoring System
(IPSS),23 18 patients were classified as low risk, 16 as intermedi-
ate-1, 4 as intermediate-2, and one as high risk MDS. Regarding
the WHO-based Prognostic Score System (WPSS),24 MDS
patients were distributed as follows: very low risk (n=11), low
risk (n=17), intermediate risk (n=6), high risk (n=4), and very
high risk (n=1). In the remaining 5 patients, metaphases could
not be obtained from cytogenetic cultures. All 44 were untreated
MDS patients and 22 of them were newly diagnosed cases seen
at the MDS outpatient clinic at the Universidade Federal de São
Paulo (UNIFESP, São Paulo, Brazil). 
At the moment of closing this study, the median follow-up
time of the whole patient series was 38 months (range 4-127
months). Overall, 20 of 44 MDS cases were transfusion depend-
ent.
In parallel, 20 PB samples from an age and sex-matched group
of adult healthy volunteers were studied as normal controls. In
addition, in order to evaluate the specificity of the immunophe-
notypic abnormalities observed among MDS patients, PB
platelets from 19 patients with different disease conditions other
than MDS were also analyzed: 4 myeloproliferative disorders (2
chronic myeloid leukemia, one essential thrombocytemia and
one myelofibrosis), 6 idiopathic thrombocytopenic purpura
patients and 9 reactive cytopenias (associated with solid tumors
in 2 cases, with sepsis in another 2, and with portal hyperten-
sion, nutritional deficiency, drug administration, lupus and
chronic kidney disease in one case each). 
Cytomorphological studies
PB and BM films were stained with May-Grünwald-Giemsa
(MGG) and cell morphology was independently evaluated with
an optical microscope by 2 expert cytomorphologists; 500 or
over nucleated cells and more than 20 megakaryocytes were
counted in each BM smear. Erythroid and neutrophil dysplasia
was defined by the presence of more than 10% BM cells with
morphological abnormalities as per WHO criteria;3 presence of
more than 15% ringed sideroblasts was also considered a diag-
nostic sign for erythroid dysplasia. Megakaryocytic dysplasia
was characterized by the presence of abnormalities (e.g.
micromegakaryocytes, nuclear hypolobulation and large
mononuclear cells) involving more than 40% of all megakary-
ocytic cells.
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Figure 1. Example of the
two-step acquisition pro-
cedure and the gating
strategy used for the
immunophenotypic iden-
tification and characteri-
zation of platelets in
stained whole PB sam-
ples. After initial acquisi-
tion of a total of 2x104
events (A), an electronic
live gate (R1) was drawn
around the platelets
based on their unique
FSC/SSC characteristics.
Then, in a second step,
information about ≥
2x104 platelets was
acquired through this
electronic live gate (B
and C). Finally, platelets
(gray events) were identi-
fied as those events
being CD41+ (R2 in
panel C) (see C-E).
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Multiparameter flow cytometry immunophenotypic studies
MFC immunophenotypic studies were systematically per-
formed at room temperature (RT) on fresh PB samples, within less
than 3 h after the sample had been obtained. Expression of
platelet-associated GP was evaluated using a FACSCalibur flow
cytometer (Becton-Dickinson, San José, CA, USA) and the follow-
ing combinations of monoclonal antibodies (MAb) were systemat-
ically used: fluorescein isothiocyanate (FITC) / phycoerythrin (PE)
/ peridinin chlorophyll protein (PerCP)-: CD42a/CD31/-; CD41b/-/-
; CD36/CD41a/-; CD63/42b/-; PAC-1/CD62P/CD61; anti-fibrino-
gen/-/-; and CD61/CD34/-. Reagents were purchased from 1)
Becton-Dickinson: CD31-PE (clone L133.1), CD34-PE (clone
8G12), CD41b-FITC (clone HIP2), CD42a-FITC (clone Beb1),
CD61-PerCP (clone RUU-PL 7F12), CD62P-PE (clone AC1.2) and
PAC-1-FITC; 2) Immunotech (IOT, Marseille, France): CD36-FITC
(clone FA6.152), CD41a-PE (clone P2), CD42b-PE (clone SZ2),
CD61-FITC (clone SZ21) and CD63-FITC (clone CLBGran/12). In
addition, an anti-fibrinogen polyclonal antiserum conjugated with
FITC (DAKO, Glostrup, Denmark) was also used to stain platelets.
Non-stained PB was used in all experiments as a negative control.
Briefly, 5 μL of whole PB was pipetted into multiple 12 x 75 mm
polystyrene tubes containing 100 μL of phosphate buffered saline
(PBS) each (pH=7.4), and stained with saturating amounts (0.5-1
μg) of the different combinations of MAb reagents. After gentle
mixing, samples were incubated for 15 min in darkness (RT) and
washed once in 2 mL PBS (5 min at 2800 rpm). The cell pellet was
then resuspended in 500 μL of PBS. No fixative or lysing solution
was used during the staining procedure.
Data acquisition was performed in two sequential steps imme-
diately after sample preparation, using the CellQUEST software
program (BD). In a first step, information on a total of 2¥104 events
corresponding to the whole PB cellularity was acquired. In a sec-
ond step, information was specifically collected for 2¥104 or more
platelets through an electronic live gate set in a forward (FSC) and
sideward light scatter (SSC) dot plot (Figure 1). Prior to data acqui-
sition, instrument settings were optimized for the flow cytometric
analysis of platelets. The Paint-a-Gate PRO software program (BD)
was used for data analysis.
Platelets were specifically identified on the basis of their unique
FSC/SSC characteristics (expressed in arbitrary mean channel lin-
ear unit values scaled from 0 to 1024) and expression of pan-
platelet GP (Figure 1). For each specific GP, results were expressed
as mean fluorescence intensity values (MFI; relative linear units
scaled from 0 to 104). Aberrant phenotypes were defined when the
patients MFI and FSC/SSC values were greater or lower than the
mean value±2 standard deviations (SD) of the mean MFI obtained
for the same GP in PB platelets from adult healthy individuals.
Immunophenotypic score
For each of the 15 platelet immunophenotypic variables ana-
lyzed, an immunophenotypic score for mild to severe alterations
was established similar to that previously described by Matarraz et
al.8 First, a value of 0, 0.5, 1 or 2 was given when the MFI value
obtained for each of the phenotypic variables evaluated was with-
in the mean±2 SD, between the mean±2 SD and the mean±3 SD,
between the mean±3 SD and the mean±4 SD and, over the
mean±4 SD of those values found for that parameter among nor-
mal PB samples, respectively. The immunophenotypic score was
then calculated for each patient by adding up the score obtained
for that patient for each of the 15 immunophenotypic parameters
evaluated.
Statistical analysis
Mean value and SD, median and range of all parameters under
study were calculated using the SPSS 13.0 software program (SPSS,
Chicago, IL, USA). Student's t-test and either the Mann-Whitney
U or the Kruskal-Wallis tests (two-sided) were used to calculate the
statistical significance of differences observed between groups for
parametric and non-parametric data, respectively. Survival curves
were plotted according to the Kaplan-Meyer method and com-
pared with the log rank test. Duration of survival was defined as
the time from diagnosis of MDS until death or the last follow-up
visit. Cox’s regression model was used for multivariate analyses.
P<0.05 was considered statistically significant.
Results
Cytomorphological features of BM megakaryocytic cells
from myelodysplastic syndrome patients
In 33 of 44 MDS patients, enough megakaryocytes were
detected on BM films to allow morphological assessment.
Megakaryocytic dysplasia was found in 17 of 33 cases
(52%) in between 50 and 98% of the cells. The most fre-
quent alterations were: hypolobulated megakaryocytes
(n=18), mononuclear large megakaryocytic cells (n=12),
megakaryocytes with widely-separated nucleus (n=8), and
presence of micromegakaryocytes (n=4).
Immunophenotypic characteristics of PB platelets in
myelodysplastic syndromes 
The overall median number of PB platelets in MDS cases
was 185¥109/L (range 4-890¥109/L). Twenty-six cases (59%)
had platelet counts over 100¥109/L, 8 (18%) between 50
and 100¥109/L and 10 showed less than 50¥109 platelets/L
in PB.
An analysis of immunophenotypic characteristics
showed platelets from MDS patients with multiple alter-
ations compared to PB platelets from healthy adults. These
included altered light scatter characteristics (FSC 32%, SSC
39%), increased and decreased expression of platelet glyco-
proteins, as well as aberrant expression of the CD34 antigen
in one case (Table 1). Interestingly, no statistically significant
difference was found between MDS patients and normal
controls regarding the expression of any of the platelet acti-
vation-associated proteins investigated (e.g. CD62P, CD63,
PAC-1 and anti-fibrinogen).
Nevertheless, immunophenotypic analysis of PB platelets
from patients with disease conditions other than MDS
showed that increased light scatter and increased CD36 and
CD31 expression were not specific for MDS, as they were
also found among non-MDS cases. In contrast, decreased
expression of CD36 (11%), CD61 (5%) (Figure 2) and
CD42a (2%), aberrant expression of CD34 (2%) and
decreased FSC values (5%) were only detected among
MDS patients. CD36 deficiency was found in 5 cases: 2
RCMD, 2 RAEB-1 and one refractory thrombocytopenia.
Most of them (4 of 5) also presented thrombocytopenia
with megakaryocytic dysplasia on morphological grounds.
In turn, CD61 deficiency was seen in 2 MDS cases (one
RCMD and one RA) that had normal platelet counts.
Megakaryocytic dysplasia was observed in one of these 2
patients. In turn, decreased expression of CD42a was iden-
tified in one case (RARS) in association with normal platelet
counts and megakaryocytic morphology. CD34 was
expressed on platelets from a RAEB-2 patient who had
thrombocytopenia and megakaryocytic dysplasia, whereas
decreased FSC values were found in 2 RA cases.
Immunophenotypic score
The overall immunophenotypic score of PB platelets
from MDS patients, ranged from 0 to 10.5 (mean 2.3±2.9),
while all controls had a score of 1.5 or under except for one
patient with cytopenias and portal hypertension who had a
score of 2. According to this score, three groups of MDS
patients could be identified: i) cases showing a normal
platelet phenotype with a score of between 0 and 1.5 (n=28,
64%); ii) patients with a score of between 2 and 3 (n=6,
14%); and iii) cases with severe platelet dysplasia and a
score of over 3 (n=10, 23%). 
It is worthy of note that high immunophenotypic scores
(>1.5) were observed in all WHO subtypes of MDS except
RAEB-1, the higher frequencies corresponding to RAEB-2
(n=2 of 5, 40%) and RCMD cases (n=8 of 14,57%) (Table
2). As could be expected, a high number of patients with
platelet counts over 100¥109 platelets/L (73 vs. 40% for
cases with less than 50¥109 platelets/L), normal megakary-
ocytic morphology (75 vs. 59%) and low-risk MDS (78 vs.
52%) had a score of 1.5 or under, although these differences
did not reach statistical significance (Table 3). Interestingly,
all cases who showed MDS-specific immunophenotypic
alterations (decreased CD36, CD61 and/or CD42a expres-
sion and positivity for CD34) displayed an immunopheno-
typic score of under 3 and all 3 refractory thrombocytope-
nia cases presented a score of between 0 and 1.5 (Table 2). 
Survival of myelodysplastic syndrome cases according
to the presence of thrombocytopenia, megakaryocytic
dysplasia and an altered platelet phenotype by MFC
The estimated median overall survival (OS) of patients
with megakaryocytic dysplasia by morphology was slightly
lower than those cases without dysplasia (80±12 vs.
108±11; P>0.05). In turn, cases with platelet counts under
100¥109/L showed a significantly shorter OS than those
with more than 100¥109 platelets/L (59±12 vs. 108±10
months, respectively; P=0.005) (Figure 3A). None of the
individual immunophenotypic abnormalities identified on
its own showed a significant impact on OS of MDS
patients. Nevertheless, a high overall platelet immunophe-
notypic score (score >1.5) was associated with a shorter OS
(mean 45±9 vs. 102±11 months, respectively; P=0.01)
(Figure 3B).
Multivariate analysis for OS showed that a high
immunophenotypic score (P=0.04) together with a high
(Int-2/high) IPSS (P=0.01) were the only independent
adverse prognostic factors for overall patient survival.
Discussion
MDS comprise a heterogeneous spectrum of disorders
characterized by a clonal dysregulation of hematopoiesis,
which is responsible for markedly altered multilineage mor-
phological patterns of BM cells associated with PB cytope-
nias.2 Such abnormalities are associated with multiple and
frequently complex cytogenetic changes25 which also trans-
a.F. sandes et al.
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Table 1. Type and frequency of immunophenotypic alterations detected
on PB platelets from MDS patients (n = 44) versus normal control sub-
jects (n=20).
Immunophenotypic aberrancy N %
Abnormal light scatter characteristics
Increased FSC 14 32%
Increased SSC 17 39%
Decreased FSC 2 5%
Increased expression of platelet glycoproteins
CD31 13 30%
CD36 12 27%
CD41a 7 16%
CD41b 4 9%
CD42a 3 7%
CD42b 4 9%
CD61 5 11%
Decreased expression of platelet glycoproteins
CD36 5 11%
CD42a 1 2%
CD61 2 5%
Expression of immature antigens
CD34 1 2%
late into aberrant antigen expression profiles during differ-
entiation and maturation of hematopoietic cells.7,26,27
Despite the increasing evidence in support of the occur-
rence of a great variety of immunophenotypic aberrations
on CD34+ precursors,6,8,9,28 as well as maturing neutrophil,
monocytic and erythroid cells10,11,13,14,29 which may con-
tribute to a more refined diagnosis and prognostic assess-
ment of MDS, so far only a few studies have been reported
in which megakaryocytic lineage cells from MDS patients
are analyzed by MFC; in addition, in one of these reports10
no altered MFC profiles for megakaryocytic cells in MDS
were reported.
Megakaryocytic dysplasia can be found by morphology
in around 40% of all MDS cases30 and it contains key diag-
nostic information. At the same time it is associated with a
poor prognosis of the disease.30,31 Similarly, multiple reports
continue to show that thrombocytopenia is also associated
with both a worse outcome and decreased survival in
MDS,8,32-34 even among low-risk MDS cases.35 In our series,
megakaryocytic dysplasia was not seen to have a significant
impact on the outcome of MDS patients. In contrast,
patients with less than 100¥109 platelets/L had a worse out-
come. Interestingly, analysis of BM films does not always
provide enough megakaryocytic-lineage cells to correctly
identify megakaryocytic dysplasia,30 as was the case in
approximately 25% of our patients, which limits the appli-
cability of this measurement.
Detection of immunophenotypic megakaryocytic dyspla-
sia has proven to be difficult, especially because of the com-
plexity of the ex vivo analysis of megakaryocytes and
megakaryoblasts by flow cytometry. Typically, megakary-
ocytic cells are large frail cells with propensity to aggregate,
which are present at low frequencies in the BM
(<0.05%).19,20 Because of this, immunophenotypic studies of
megakaryocytic lineage cells require large volumes of high-
ly cellular BM samples and complex methods for specific
purification/selection of megakaryocytic cells for further
analyses.1.8,21,22 Alternatively, the MFC study of PB platelets
may offer many advantages as regards the detection of
megakaryocytic dysplasia: it is a non-invasive method that
requires small volumes of PB even in severe thrombocy-
topenic patients, and it is methodologically feasible, fast
and reproducible.36
Therefore, in the present study we investigated the
immunophenotypic profiles of PB platelets from MDS
patients compared with healthy subjects. Overall, multiple
distinct flow cytometric abnormalities were found on
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Table 2. Distribution of MDS patients, healthy adults and non-MDS
patients according to the MFC immunophenotypic score of peripheral
blood platelets.
Immunophenotypic platelet score N
0-1.5 >  1.5
MDS patients 28 16 44
RA 6 3 9
RARS 7 2 9
RCMD 6 8 14
RAEB-1 2 0 2
RAEB-2 3 2 5
RT 3 0 3
5q- syndrome 1 1 2
Normal controls 20 0 20
Non-MDS patients 18 1 19
ITP 6 0 6
CMN 4 0 4
Reactive cytopenias 8 1 9
RA: refractory anemia; RARS: refractory anemia with ringed sideroblasts; RCMD: refrac-
tory cytopenia with multilineage dysplasia; RAEB-1: refractory anemia with excess of
blasts type 1; RAEB-2: refractory anemia with excess of blasts type 2; RT: refractory
thrombocytopenia; ITP: idiopathic thrompocytopenic purpura; CMN: chronic myelopro-
liferative neoplasm.
Figure 2. Bivariate dot
plots and single-para-
meter histograms
illustrating some of
the immunophenotyp-
ic alterations present
on PB platelets from
MDS patients. (A)
CD36 expression on
platelets from a nor-
mal control (black)
and an MDS patient
(gray). (B) CD61
expression by normal
(black) versus MDS
(gray) platelets.
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platelets from MDS patients. These included: altered light
scatter properties, over and underexpression of platelet
associated GP and asynchronous antigen expression. Of all
the different alterations identified, decreased expression of
CD36, CD42a and CD61, together with asynchronous
CD34 expression, were the only alterations that were
observed exclusively among MDS cases. Despite the fact
that the other aberrations were not specific for MDS, and
that they were also present in platelets from other (differ-
ent) pathological conditions, MDS cases frequently showed
a higher number and severity of abnormalities, as reflected
by a higher immunophenotypic score. Importantly, all
healthy controls and non-MDS cases except one (score of
2), showed a low immunophenotypic score. Because of
this, those cases with scores of 2 or under should be consid-
ered with caution, in order to keep false positive and false
negative results to a minimum. Overall, it should also be
emphasized that a combination of both specific and/or
multiple alterations is required to increase the specificity for
MDS of the platelet abnormalities described here, in line
with previous reports of MDS-associated phenotypic alter-
ations of other hematopoietic cell compartments.8,11,16,17
Two of our MDS cases showed abnormally decreased
expression of CD61, in association with normal levels of
CD41a (GPIIb-α) and CD41b (GPIIb-b) and normal PB
platelet counts. In turn, reduced levels of CD42b and/or
CD42a were found in only one patient. Acquired deficien-
cy of platelet GP in patients with hematologic neoplasms
has sometimes been reported. Berndt et al.37 reported a
case of juvenile MDS with loss of CD42a on platelets
(similar to what is seen in patients with Bernard-Soulier's
syndrome). Also, acquired Glanzmann thrombasthenia
due to anti-GPIIb/IIIa auto-antibodies is usually associated
with autoimmune conditions38 and has been reported in
both non-Hodgkin’s38 (NHL) and Hodgkin’s lymphomas.39
In turn, decreased levels of CD42a have also been
described in platelets from AML40 and MDS patients.41 In
this latter study,41 reduced amounts of CD42b were
reported to be a common finding in MDS cases, although
no patient showed complete lack or decreased expression
of CD36.
The CD36 GP (GP IV) expressed on the platelet surface,
acts as a receptor for thrombospondin and collagen; it is
expressed by normal platelets, monocytes, nucleated red
cell precursors and endothelial cells.42 CD36 deficiency was
first described in 1989 by Ikeda et al.43 in a case that was
refractory to platelet transfusion due to the presence of a
new anti-platelet antibody, named anti-Naka. Yamamoto et
al.44 later showed that the Naka epitope is part of the CD36
molecular structure and that in the patients mentioned
above this protein was not well expressed. Congenital
CD36 deficiency is not directly associated with either quan-
titative or qualitative platelet disorders. However, when in
contact with this antigen (e.g. through transfusion and/or
pregnancy), CD36-deficient patients may develop allo-anti-
bodies against platelets leading to transfusion refractoriness,
a.F. sandes et al.
900 haematologica | 2012; 97(6)
Table 3. Distribution of MDS patients according to the MFC
immunophenotypic score of platelets versus platelet counts,
megakaryocytic dysplasia, IPSS subtype of the disease, cytogenetic
risk group and bone marrow flow cytometric abnormalities.
Immunophenotypic platelet score N
0-1.5 >  1.5
N. of cases 28 16 44
N. of platelets  (¥109/L)*
< 50 4 6 10
50-100 5 3 8
> 100 19 7 26
Megakaryocytic dysplasia 33
Absent 12 4 16
Present 10 7 17
IPSS group 39
Low risk MDS 14 4 18
Int/high risk MDS 11 10 21
Cytogenetic risk group 39
Low risk
Normal karyotype 16 8 24
Del(20q) 3 1 4
Del(5q) 2 1 3
Intermediate risk
+8 2 0 2
Others 2 4 6
Flow abnormalities in bone marrow 
Blasts/immature cells 23/26 15/16 38/42
Maturing neutrophils 21/26 16/16 37/42
Monocytic cells 17/26 16/16 33/42
Erythroblasts 17/26 11/15 28/41
Results expressed as number of cases or as number of cases/total cases. *Platelet
count: median 185¥109/L (4-890x109/L). The case with 890¥109/L corresponded to a
5q- syndrome (V617F JAK2 mutation negative) 
Figure 3. Overall survival of MDS patients according to PB platelet
(PLT) counts (A) and the platelet immunophenotypic score (B).
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posttransfusional purpura and neonatal alloimune throm-
bocytopenia.42,45 Two types of CD36 deficiency have been
described so far: type I cases show reduced CD36 expres-
sion on platelets and monocytes and type II subjects show
CD36 deficiency restricted to platelets.46 Association of
CD36 deficiency and a clonal hematologic malignancy has
been described in only one case of NHL (type I deficiency).47
In contrast, here we show that CD36 deficiency is a rela-
tively common finding in MDS, being associated in most
cases with both thrombocytopenia and megakaryocytic
dysplasia. From our CD36-deficient MDS patients, only
one case presented type I deficiency, as both monocytes
and NRBC erythrocytes were CD36-. The precise current
prevalence of CD36 deficiency in the Brazilian and the
Spanish populations is not known. Despite this, the fre-
quency of CD36 deficiency observed among our MDS
patients was by far superior to that reported in the literature
for both congenital CD36 deficiency44,48,49 and MDS,41 inde-
pendently of ethnic origin. The reasons for these differences
require further investigation. 
Based on the overall immunophenotypic profile of PB
platelets, variable immunophenotypic scores were found
among MDS patients, with a significant proportion of cases
showing immunophenotypic scores clearly higher than
those observed among normal and reactive PB platelets.
Interestingly, some patients with unilineage dysplasia (RA
and RARS) presented high (>1.5) immunophenotypic
scores or deficient GP expression profiles, supporting the
existence of multilineage involvement already among these
subgroups of MDS patients. This may imply that the study
of platelets by MFC, in addition to cytomorphology, may
contribute to a more robust distinction between a true uni-
lineage versusmultilineage dysplasia, as is also suggested by
others.16,17,50 In addition, the immunophenotypic platelet
score showed an important prognostic impact on the out-
come of MDS patients, independently of the WHO and
IPSS subtypes, the presence of megakaryocytic dysplasia
and the PB platelet count, cases with high immunopheno-
typic scores showing a shorter overall survival.
Interestingly, although an association between thrombocy-
topenia and poor patient outcome has been described in
large series of MDS patients,33,34 in our study approximately
26% (7 of 26 cases) of those patients showing normal
platelet counts had a high immunophenotypic score, rein-
forcing the potential added value of immunophenotyping
to the number of platelets in PB. 
In contrast, some cases with morphological megakary-
ocytic dysplasia and thrombocytopenia showed low
immunophenotypic scores. Apoptosis of dysplastic
megakaryocytes and shortened platelet life expectancy in
the BM,51,52 together with a decreased platelet release by the
dysplastic megakaryocytic precursors53 reported in MDS,
might contribute to explain the absence of an altered
platelet immunophenotype in these cases, because under
these conditions a normal immunophenotypic score may
result from the immunophenotypic analysis of residual nor-
mal, rather than dysplastic, PB platelets. 
There did not seem to be a significant difference in base-
line platelet activation status as assessed by flow cytometry
(e.g. CD62P levels) between MDS and healthy subjects.
Despite this and the fact that no bleeding complications
were detected among our patients, correlation of the pres-
ence and type of platelet imunophenotypic alterations with
the functionality of the platelets by other tests, such as
bleeding time, PFA-100 and platelet aggregation, may pro-
vide further insight into the potential direct functional
impact of the phenotypic alterations observed here on MDS
platelets.
In summary, the present study shows the presence of
altered platelet immunophenotypes by MFC in almost half
of all MDS cases. Such alterations are highly specific of
MDS because they are not observed in other conditions
(e.g. deficiency of CD36, CD61, CD42a and expression of
CD34+) or they reflect the alteration of multiple markers
that translate into high immunophenotypic scores. From a
clinical point of view, assessment of aberrant antigen
expression profiles associated with a high immunopheno-
typic platelet score may also help to better identify high-risk
MDS cases. However, due to the relatively limited number
of cases analyzed in this pilot study, further analyses of larg-
er series of patients are needed to confirm our preliminary
observations.
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